[New CCR5 inhibitor antiretroviral drugs and integrase inhibitors].
Copyright policy )[New CCR5 inhibitor antiretroviral drugs and integrase inhibitors].
Two new antiretroviral drugs belonging to a new drug family have recently been marketed in Spain. These are maraviroc (CCR5 correceptor inhibitor) and raltegravir (integrase inhibitor). These have the advantage of not presenting crossed resistance with other previously administered antiretroviral drugs, converting them into the cornerstone of the rescue treatment in the patient infected by a multiresistant viral strain. The scientific evidence available on these two drugs is reviewed in this work and its indications in the HIV infected patient are discussed.
Maraviroc, Cyclohexanes, HIV Fusion Inhibitors, Raltegravir Potassium, CCR5 Receptor Antagonists, Humans, Integrase Inhibitors, Triazoles, Pyrrolidinones
Maraviroc, Cyclohexanes, HIV Fusion Inhibitors, Raltegravir Potassium, CCR5 Receptor Antagonists, Humans, Integrase Inhibitors, Triazoles, Pyrrolidinones
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!